Vishnu C Ramani

List of Publications by Citations

13 papers	1,182 citations	12 h-index	13 g-index
13 ext. papers	1,344 ext. citations	8.3 avg, IF	4.14 L-index

#	Paper	IF	Citations
13	Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. *Journal of Biological Chemistry*, **2013**, 288, 10093-10099	5.4	228
12	SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. *Clinical Cancer Research*, **2011**, 17, 1382-93	12.9	185
11	The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. *FEBS Journal*, **2013**, 280, 2294-306	5.7	135
10	Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. *Matrix Biology*, **2018**, 65, 104-118	11.4	125
9	Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. *Journal of Biological Chemistry*, **2011**, 286, 6490-9	5.4	92
8	Heparanase is a host enzyme required for herpes simplex virus-1 release from cells. *Nature Communications*, **2015**, 6, 6985	17.4	88
7	Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. *Journal of Biological Chemistry*, **2012**, 287, 9952-9961	5.4	82
6	Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. *Oncotarget*, **2016**, 7, 1598-607	3.3	66
5	Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. *Matrix Biology*, **2016**, 55, 22-34	11.4	62
4	Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. *Cancer Research*, **2010**, 70, 8329-38	10.1	54
3	Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. *Matrix Biology*, **2014**, 35, 215-22	11.4	49
2	Heparanase promotes myeloma stemness and in vivo tumorigenesis. *Matrix Biology*, **2020**, 88, 53-68	11.4	16
1	Shed syndecan-1 drives tumor progression by binding to the cell surface and translocating to the nucleus. *FASEB Journal*, **2013**, 27, 595.1	0.9	